Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Hypotension | Research article

Intradialytic hypotension is an important risk factor for critical limb ischemia in patients on hemodialysis

Authors: Ryo Matsuura, Sumi Hidaka, Takayasu Ohtake, Yasuhiro Mochida, Kunihiro Ishioka, Kyoko Maesato, Machiko Oka, Hidekazu Moriya, Shuzo Kobayashi

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Critical limb ischemia (CLI) and intradialytic hypotension (IDH) are common complications in patients on hemodialysis (HD). However, limited data are available on whether IDH is related to CLI in these patients. The aim of this retrospective study was to evaluate whether IDH is a risk factor for CLI in HD patients.

Methods

We examined the frequency of IDH in 147 patients who received HD between January 1 and June 30, 2012. Blood pressure was measured during HD every 30 min and IDH was defined as a ≥ 20 mmHg fall in systolic blood pressure compared to 30 min before and a nadir intradialytic systolic blood pressure < 90 mmHg. The primary study outcome was newly developed CLI requiring revascularization treatment or CLI-related death. We assessed the association of IDH with outcome using a multivariable subdistribution hazard model with adjustment for male, age, smoking and history of cardiovascular disease.

Results

The median follow-up period was 24.5 months. Fifty patients (34%) had episodes of IDH in the study entry period. During follow-up, 14 patients received endovascular treatment and CLI-related death occurred in 1 patient. Factors associated with incident CLI in univariate analysis were age, smoking, diabetes mellitus, peripheral arterial disease, history of cardiovascular disease, and IDH. IDH was significantly associated with the outcome with the subdistribution hazard ratio of 3.13 [95% confidence interval, 1.05–9.37].

Conclusions

IDH was an independent risk factor for incident CLI in patients on HD.
Literature
1.
go back to reference Ohtake T, Oka M, Ikee R, Mochida Y, Ishioka K, Moriya H, et al. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53:676–83.CrossRef Ohtake T, Oka M, Ikee R, Mochida Y, Ishioka K, Moriya H, et al. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53:676–83.CrossRef
2.
go back to reference Orimoto Y, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Yamada T, et al. The prognosis of patients on hemodialysis with foot lesions. J Vasc Surg. 2013;58:1291–9.CrossRef Orimoto Y, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Yamada T, et al. The prognosis of patients on hemodialysis with foot lesions. J Vasc Surg. 2013;58:1291–9.CrossRef
3.
go back to reference Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Rosenfield K, et al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–15.CrossRef Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Rosenfield K, et al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–15.CrossRef
4.
go back to reference Nakano M, Hirano K, Iida O, Yamauchi Y, Soga Y, Kawasaki D, et al. Clinical efficacy of infrapopliteal endovascular procedures for hemodialysis patients with critical limb ischemia. Ann Vasc Surg. 2015;29:1225–34.CrossRef Nakano M, Hirano K, Iida O, Yamauchi Y, Soga Y, Kawasaki D, et al. Clinical efficacy of infrapopliteal endovascular procedures for hemodialysis patients with critical limb ischemia. Ann Vasc Surg. 2015;29:1225–34.CrossRef
5.
go back to reference Hoshina K, Yamamoto K, Miyata T, Watanabe T. Outcomes of critical limb ischemia in hemodialysis patients after distal bypass surgery- poor limb prognosis with stage 4 wound, ischemia, and foot infection (WIfI). Circ J. 2016;80:2382–7.CrossRef Hoshina K, Yamamoto K, Miyata T, Watanabe T. Outcomes of critical limb ischemia in hemodialysis patients after distal bypass surgery- poor limb prognosis with stage 4 wound, ischemia, and foot infection (WIfI). Circ J. 2016;80:2382–7.CrossRef
6.
go back to reference Fallon JM, Goodney PP, Stone DH, Patel VI, Nolan BW, Kalish JA, et al. Outcomes of lower extremity revascularization among the hemodialysis-dependent. J Vasc Surg. 2015;62:1183–91 e1.CrossRef Fallon JM, Goodney PP, Stone DH, Patel VI, Nolan BW, Kalish JA, et al. Outcomes of lower extremity revascularization among the hemodialysis-dependent. J Vasc Surg. 2015;62:1183–91 e1.CrossRef
7.
go back to reference Kobayashi S. Cardiovascular events in chronic kidney disease (CKD)—an importance of vascular calcification and microcirculatory impairment. Ren Replace Ther. 2016;2:55.CrossRef Kobayashi S. Cardiovascular events in chronic kidney disease (CKD)—an importance of vascular calcification and microcirculatory impairment. Ren Replace Ther. 2016;2:55.CrossRef
8.
go back to reference Nusair MB, Rajpurohit N, Alpert MA. Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardiorenal Med. 2012;2:117–24.CrossRef Nusair MB, Rajpurohit N, Alpert MA. Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardiorenal Med. 2012;2:117–24.CrossRef
9.
go back to reference O'Hare AM, Hsu CY, Bacchetti P, Johansen KL. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol. 2002;13:497–503.PubMed O'Hare AM, Hsu CY, Bacchetti P, Johansen KL. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol. 2002;13:497–503.PubMed
10.
go back to reference Okamoto K, Oka M, Maesato K, Ikee R, Mano T, Moriya H, et al. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis. 2006;48:269–76.CrossRef Okamoto K, Oka M, Maesato K, Ikee R, Mano T, Moriya H, et al. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis. 2006;48:269–76.CrossRef
11.
go back to reference Stefansson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K, et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol. 2014;9:2124–32.CrossRef Stefansson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K, et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol. 2014;9:2124–32.CrossRef
12.
go back to reference Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–20.CrossRef Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–20.CrossRef
13.
go back to reference Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patietns on chronic hemodialysis. Ther Apher Dial. 2012;16:387–435.CrossRef Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patietns on chronic hemodialysis. Ther Apher Dial. 2012;16:387–435.CrossRef
14.
go back to reference Orofino L, Marcen R, Quereda C, Villafruela JJ, Sabater J, Matesanz R, et al. Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate benefisical for all patients? Am J Nephrol. 1990;10:177–80.CrossRef Orofino L, Marcen R, Quereda C, Villafruela JJ, Sabater J, Matesanz R, et al. Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate benefisical for all patients? Am J Nephrol. 1990;10:177–80.CrossRef
15.
go back to reference Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015;26:724–34.CrossRef Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015;26:724–34.CrossRef
16.
go back to reference Hasanadka R, McLafferty RB, Moore CJ, Hood DB, Ramsey DE, Hodgson KJ. Predictors of wound complications following major amputation for critical limb ischemia. J Vasc Surg. 2011;54:1374–82.CrossRef Hasanadka R, McLafferty RB, Moore CJ, Hood DB, Ramsey DE, Hodgson KJ. Predictors of wound complications following major amputation for critical limb ischemia. J Vasc Surg. 2011;54:1374–82.CrossRef
17.
go back to reference O'Brien-Irr MS, Dosluoglu HH, Harris LM, Dryjski ML. Outcomes after endovascular intervention for chronic critical limb ischemia. J Vasc Surg. 2011;53:1575–81.CrossRef O'Brien-Irr MS, Dosluoglu HH, Harris LM, Dryjski ML. Outcomes after endovascular intervention for chronic critical limb ischemia. J Vasc Surg. 2011;53:1575–81.CrossRef
18.
go back to reference Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016;151:1070–7.CrossRef Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016;151:1070–7.CrossRef
19.
go back to reference London GM. Ultrafiltration intensification for achievement of dry weight and hypotension control is not always the therapeutic gold standard. J Nephrol. 2011;24:395–7.CrossRef London GM. Ultrafiltration intensification for achievement of dry weight and hypotension control is not always the therapeutic gold standard. J Nephrol. 2011;24:395–7.CrossRef
20.
go back to reference Ohtake T, Kobayashi S. Impact of vascular calcification of cardovascular mortality in hemodialysis patients: clinical significance, mechanisms and possible strayegies for treatment. Ren Replace Ther. 2017;3:13.CrossRef Ohtake T, Kobayashi S. Impact of vascular calcification of cardovascular mortality in hemodialysis patients: clinical significance, mechanisms and possible strayegies for treatment. Ren Replace Ther. 2017;3:13.CrossRef
21.
go back to reference Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, contorlled trial. Hypertension. 2009;53:500–7.CrossRef Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, contorlled trial. Hypertension. 2009;53:500–7.CrossRef
22.
go back to reference Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int. 2008;73:759–64.CrossRef Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int. 2008;73:759–64.CrossRef
23.
go back to reference Ok E, Asci G, Chazot C, Ozkahya M, Mees EJ. Controversies and poblems of volume control and hypertension in hemodialysis. Lancet. 2016;388:285–93.CrossRef Ok E, Asci G, Chazot C, Ozkahya M, Mees EJ. Controversies and poblems of volume control and hypertension in hemodialysis. Lancet. 2016;388:285–93.CrossRef
24.
go back to reference Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.CrossRef Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.CrossRef
25.
go back to reference Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2017;32:1723–30.PubMedPubMedCentral Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2017;32:1723–30.PubMedPubMedCentral
26.
go back to reference Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247–88.CrossRef Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247–88.CrossRef
Metadata
Title
Intradialytic hypotension is an important risk factor for critical limb ischemia in patients on hemodialysis
Authors
Ryo Matsuura
Sumi Hidaka
Takayasu Ohtake
Yasuhiro Mochida
Kunihiro Ishioka
Kyoko Maesato
Machiko Oka
Hidekazu Moriya
Shuzo Kobayashi
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1662-x

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.